Peptide questions · Eloralintide

Eloralintide side effects: what studies and users report

Reviewed Evidence: ModeratePublished by PepVault

The side effects most commonly reported for eloralintide are nausea, fatigue and constipation, among 8 the library lists; the library’s evidence on it includes controlled trials in people.

Its safety note opens: eloralintide has no label: it is still in trials.

What is commonly reported with eloralintide

  • Nausea
  • Fatigue
  • Constipation
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • Hair thinning
  • Injection site reaction

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other metabolic & GLP-1 compounds the library lists it for
EffectAlso listed for (of 24)
Nausea21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more
Fatigue7: Semaglutide, Tirzepatide, Retatrutide, Dulaglutide and 3 more
Constipation13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more
Diarrhea20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more
Vomiting18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more
Decreased appetite9: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 5 more
Hair thinningNone: listed for Eloralintide alone
Injection site reaction1: Mazdutide
A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Track eloralintide in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which eloralintide side effects the metabolic & GLP-1 group shares

Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Eloralintide shares 7 of its 8 listed effects with at least one other metabolic & GLP-1 compound; hair thinning is listed for eloralintide alone.

What the eloralintide safety notes say

The library’s safety note

Eloralintide has no label: it is still in trials. In the 48-week phase 2 trial, nausea affected 11% on 1 mg and 13% on 3 mg (about the same as 14% on placebo), and 25% to 64% on the higher doses; fatigue rose with dose to 43% to 46% at 9 mg vs 12% on placebo. Most of these were mild to moderate, and Lilly reported fewer of them with a slower step-up. The trial's posted results also list a slower heart rate (bradycardia) in a few people on 6 and 9 mg and none on placebo, and hair thinning in about 1 in 9 on 9 mg (6 of 54) and none on placebo. In Lilly's later trial in type 2 diabetes, 0% to 10.8% on eloralintide alone stopped for side effects. Long-term safety is not yet known. These are trial findings to review with your clinician.

The library’s interaction note

No interaction studies have been published. In the phase 1 trial, eloralintide slowed stomach emptying only a little after the first dose, and the effect faded with weekly dosing, so the authors expect less delay to oral medicines than with older amylin drugs; this still needs confirming. It is not a GLP-1, and Lilly is testing it on top of tirzepatide (EloraTZP), but the GI side effects add up in the pair. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the eloralintide reports come from

The library rates the evidence on eloralintide as moderate: animal studies plus some human data.

Of the library’s 8 research notes on eloralintide, 6 rest on randomized trials and 2 on clinical data.

Our 2 study pages on eloralintide: 2 randomized trials.

So eloralintide has controlled trials in people to set its listed effects against.

What our eloralintide study pages report on safety

Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1

Randomized trial, human, 2026: Appetite loss was the side effect seen most often, in 19% of people on the drug; others included COVID-19 (11%), fatigue (11%) and headache (12%), and most side effects were mild. Gut problems were less frequent, with vomiting in 4%, nausea in 8% and diarrhea in 10%.

Eloralintide: -4.4% body weight at week 4 in a single-dose trial

Randomized trial, human, 2025: In the human trial, participants on eloralintide reported 16 adverse events, and 15 of the 16 were mild; there were 4 gastrointestinal events, including one moderate vomiting event. The human part was a small phase 1 safety trial of single doses in healthy people, with weight checked at week 4, so it does not show long-term weight loss or safety in people with obesity.

Questions people ask

What are the side effects of eloralintide?

The side effects most commonly reported for eloralintide are nausea, fatigue and constipation, among 8 the library lists; the library’s evidence on it includes controlled trials in people.

Do eloralintide’s side effects come from human studies?

The library rates the evidence on eloralintide as moderate, and the library’s evidence on it includes controlled trials in people.

Which eloralintide side effects are its own?

Among the metabolic & GLP-1 compounds, the library lists hair thinning for eloralintide alone.

Does eloralintide interact with other medicines?

The library’s interaction note on eloralintide begins: No interaction studies have been published.

More on eloralintide

Track it in the app

PepVault for iPhone

Track eloralintide in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo